<DOC>
	<DOCNO>NCT00473330</DOCNO>
	<brief_summary>This study Phase III , double-masked , multicenter , randomize , sham injection-controlled study efficacy safety ranibizumab injection patient clinically significant macular edema center involvement ( CSME-CI ) secondary diabetes mellitus ( Type 1 2 ) . This study identical design study NCT00473382 ( Protocol ID FVF4168g ) . The open-label extension phase study stop receive FDA approval study drug ( ranibizumab ) diabetic macular edema .</brief_summary>
	<brief_title>A Study Ranibizumab Injection Subjects With Clinically Significant Macular Edema ( ME ) With Center Involvement Secondary Diabetes Mellitus ( RISE )</brief_title>
	<detailed_description>This study compose 3 phase : ( 1 ) A 24-month controlled treatment period ( monthly treatment ranibizumab 0.3 mg , ranibizumab 0.5 mg , sham injection ) follow ( 2 ) 12-month treatment period patient randomized sham group discontinue treatment ( still mask ) could choose receive monthly ranibizumab 0.5 mg 2 ranibizumab treatment group continue treatment receive first 2 year . Patients discontinue treatment Month 36 eligible continue treatment ranibizumab 0.5 mg need ( pro nata , PRN ) ( 3 ) extension phase study 2 year , result 5 year possible total treatment time patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Willingness provide write informed consent , U.S. sit , Health Insurance Portability Accountability Act ( HIPAA ) authorization , country , applicable accord national law . Age ≥ 18 year . Diabetes mellitus ( Type 1 2 ) . Retinal thicken secondary diabetes mellitus ( DME ) involve center fovea central macular thickness ≥ 275 µm center subfield assess optical coherence tomography ( OCT ) . Best correct visual acuity ( BCVA ) score study eye 20/40 20/320 approximate Snellen equivalent use Early Treatment Diabetic Retinopathy Study ( ETDRS ) protocol initial test distance 4 meter . Decrease vision determine primarily result DME cause . For sexually active woman childbearing potential , use appropriate form contraception ( abstinence ) duration study . Ability ( opinion investigator ) willingness return schedule visit assessment . History vitreoretinal surgery study eye . Panretinal photocoagulation ( PRP ) macular laser photocoagulation study eye within 3 month screen . Previous use intraocular corticosteroid study eye ( eg , triamcinolone acetonide [ TA ] ) within 3 month screen . Previous treatment antiangiogenic drug either eye ( pegaptanib sodium , anecortave acetate , bevacizumab , ranibizumab , etc ) within 3 month Day 0 ( first day treatment ) visit . Proliferative diabetic retinopathy ( PDR ) study eye , exception inactive , regress PDR . Iris neovascularization , vitreous hemorrhage , traction retinal detachment , preretinal fibrosis involve macula study eye . Concurrent Ocular Conditions Vitreomacular traction epiretinal membrane study eye . Ocular inflammation ( include trace ) study eye . History idiopathic autoimmune uveitis either eye . Structural damage center macula study eye likely preclude improvement VA follow resolution macular edema , include atrophy retinal pigment epithelium ( RPE ) , subretinal fibrosis , organize hardexudate plaque . Ocular disorder study eye may confound interpretation study result , include retinal vascular occlusion , retinal detachment , macular hole , choroidal neovascularization ( CNV ) cause ( eg , agerelated macular degeneration ( AMD ) , ocular histoplasmosis , pathologic myopia ) . Concurrent disease study eye would compromise visual acuity require medical surgical intervention study period . Cataract surgery study eye within 3 month , yttriumaluminumgarnet ( YAG ) laser capsulotomy within past 2 month , intraocular surgery within 90 day precede Day 0 . Aphakia absence posterior capsule study eye . Uncontrolled glaucoma previous filtration surgery study eye . Spherical equivalent refractive error study eye 8 diopter myopia . Evidence examination infectious blepharitis , keratitis , scleritis , conjunctivitis either eye current treatment serious systemic infection . Uncontrolled blood pressure . History cerebral vascular accident myocardial infarction within 3 month prior Day 0 . Uncontrolled diabetes mellitus . Renal failure require dialysis renal transplant . Participation investigational trial within 30 day prior screen involve treatment drug ( exclude vitamin mineral ) device . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication . Pregnancy lactation . History allergy fluorescein . History allergy ranibizumab injection relate molecule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lucentis</keyword>
	<keyword>DME</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Vision loss</keyword>
</DOC>